The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
17-Oct-16
$1.4 billion
Target:
Save-A-Lot
Acquiror:
Affiliate of Onex Corporation
Advised SUPERVALU, Inc., one of the largest grocery wholesalers and retailers in the US, on the sale of its Save-A-Lot business, a leading hard-discount grocery retailer in the U.S., to an affiliate of Onex Corporation
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
17-Jun-16
$310 million
Target:
Dobbies Garden Centres
Acquiror:
Investor group led by Midlothian Capital Partners and Hattington Capital
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
10-Jun-16
$NA
Target:
Giraffe restaurants
Acquiror:
Boparan Private Office
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan
01-Jun-16
$221 million
Target:
Patties Foods Ltd
Acquiror:
Pacific Equity Partners
Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement
04-May-16
$NA
Target:
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Acquiror:
Ligand Pharmaceuticals
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
19-Apr-16
$NA
Target:
Total Care Medicaid Plan
Acquiror:
Molina Healthcare, Inc.
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
22-Dec-15
$NA
Target:
Hortifruti
Acquiror:
Partners Group
Advised Hortifruti, Brazil's number one premium retailer of healthy food, on the sale of a significant minority stake to Partners Group, a global private markets investment manager
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
29-Oct-15
$275 million
Target:
Aesynt, Inc.
Acquiror:
Omnicell, Inc.
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
06-Jul-15
$910 million
Target:
Altegra Health, Inc.
Acquiror:
Emdeon Inc.
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
08-Jun-15
$45 million
Target:
Aralez Pharmaceuticals Inc.
Acquiror:
QLT Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc